AbbVie (ABBV) Plans $7.5B Tender Offer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
AbbVie (ABBV) Highlights New Investigational Data for Elagolix at 2018 ACOG Meetings
April 27, 2018 8:10 AM EDTAbbVie (NYSE: ABBV) today announced that data for elagolix, an investigational, orally administered gonadotropin-releasing hormone (GnRH) receptor antagonist, will be presented at the 2018 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting in Austin, TX.
"We strive to improve care for women living with endometriosis and uterine fibroids," said Dawn Carlson, M.D., M.P.H., vice president, general medicine development. "These presentations highlight safety and efficacy data for elagolix and... More
Abbvie (ABBV) PT Raised to $101 at Deutsche Bank
April 27, 2018 7:49 AM EDTDeutsche Bank raised its price target on Abbvie (NYSE: ABBV) to $101.00 (from $100.00) while maintaining a Hold rating.
... MoreAbbVie (ABBV) Tops Q1 EPS by 8c, Raises FY EPS Guidance
April 26, 2018 7:48 AM EDTAbbVie (NYSE: ABBV) reported Q1 EPS of $1.87, $0.08 better than the analyst estimate of $1.79. Revenue for the quarter came in at $7.93 billion versus the consensus estimate of $7.6 billion.
GUIDANCE:
AbbVie sees FY2018 EPS of $7.66-$7.76, versus the consensus of... More
